PBAC's latest decision on Zoster virus vaccine live: Deferred (2014). Considered for Prevention of herpes zoster and post-herpetic neuralgia in immunocompetent people aged 70 years (ongoing cohort) and 71-79 years (catch-up cohort).
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2014
Submissions
2
2014 → 2014
Eligible population
Immunocompetent people aged 70 years (ongoing cohort) and 71-79 years (catch-up cohort).
standard medical management of patients with zoster / PHN
Economic model
CUA
ICER note
Economic model presented but ICER values not stated in public text; likely commercially sensitive.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2014) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.